Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective study of switch to 3TC monotherapy in patients with virologic failure and 3TC resistance
2004-002633-39Phase 4Active
- Sponsor
- University Hospital Zurich
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lamivudine in human immunodeficiency virus infection (HIV), sponsored by University Hospital Zurich. Primary endpoints: Change in CD4+ lymphocyte count from baseline to week 24 and Change in CD4+ lymphocyte count from baseline to week 48. Started Dec 2004; status: active.
02
Drugs
lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2004-002633-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002633-39.